Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda

WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers received the single–dose vaccine at Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda today.

There are currently no vaccines or antiviral treatments approved to treat Marburg virus disease. Marburg is a filovirus, in the same family as the virus that causes Ebola. Like Ebola, Marburg virus disease spreads between people via direct contact with the blood or other bodily fluids of infected people, is highly virulent, and causes hemorrhagic fever. The disease has a fatality rate of up to 88%.

Based on the ChAd3 platform, Sabin's single–dose investigational Marburg vaccine was found to be promising in Phase 1 clinical and non–clinical studies, with results showing it to be safe, while eliciting rapid and robust immune responses.

Dr. Betty Mwesigwa, deputy executive director of MUWRP, is the principal investigator for the Kampala portion of the Sabin–sponsored trial. Participants will also be enrolled a few weeks later at a second site at the Kenya Medical Research Institute in Siaya, Kenya, with Dr. Videlis Nduba as principal investigator. In all, 125 volunteers will participate in the trial.

"We have an extraordinary opportunity here to improve our preparedness to save lives and protect people from a deadly and unforgiving disease that typically strikes under–resourced countries first and most," says Amy Finan, Sabin's Chief Executive Officer. "Sabin's Phase 2 clinical trial builds on a solid safety and immunogenicity foundation and we are hoping it will generate the information needed to move the vaccine toward licensure."

The number of Marburg outbreaks in Africa has climbed steadily in recent years. Two outbreaks of Marburg virus disease have occurred already this year: Equatorial Guinea reported its first ever documented Marburg outbreak, which killed 12 people, followed by Tanzania, where six people succumbed to the virus. Communities in Uganda and Kenya are familiar with Marburg virus disease, having been ravaged by outbreaks over multiple years in the last few decades.

"Makerere University Walter Reed Project (MUWRP) is delighted to partner with the Sabin Vaccine Institute to launch the clinical testing for a preventive Marburg vaccine," says Dr. Mwesigwa. "Most Marburg virus disease outbreaks have originated in Africa. Uganda alone has registered 4 outbreaks of the disease. We urgently need a vaccine against Marburg because of its potential to cause epidemics with significant death rates. It is imperative for us to test candidate vaccines in Uganda, a country prone to these outbreaks. This work will contribute new knowledge to inform the scientific discovery for an effective vaccine against the deadly Marburg virus."

The Phase 2 clinical trial for Sabin's Marburg vaccine will continue to evaluate safety and immunogenicity for the vaccine, this time among a larger group of individuals. This is a randomized, placebo–controlled, double–blind study, meaning that neither the participants nor the researchers will know whether trial participants receive a vaccine dose or a placebo dose until after the trial is over, an approach used to help reduce experimental bias.

Participants in the clinical trial will be monitored for a full year and will include both younger (18–50 years) and older age groups (51–70 years). Interim results are expected next year. In addition to the current trial in Uganda and Kenya, Sabin plans to conduct a similar Phase 2 clinical trial for Marburg in the U.S.

The Marburg vaccine trials are supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, under multi–year contracts between the organizations, including most recently a $36.4 million award for vaccine development and production.

Similarly, BARDA has invested in Sabin for advancing ChAd3 Sudan ebolavirus vaccine candidate, including awarding $28 million this August for Phase 2 clinical trials in the U.S.

To date, Sabin has received around $215 million in contract awards from BARDA for furthering vaccine research and development against Sudan ebolavirus and Marburg virus diseases.

BARDA and Sabin began working together in September 2019 to develop the two monovalent vaccine candidates. Sabin's Sudan ebolavirus vaccine candidate was the first to arrive in Uganda last year during the disease outbreak that left 55 people dead. Sabin has also initiated plans for a Phase 2 Sudan ebolavirus vaccine clinical trial in Uganda and Kenya.

This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract numbers 75A50119C00055 and 75A50123C00010.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non–profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on X, @SabinVaccine.About Sabin's Vaccine R&D Using the ChAd3 Platform.

About Sabin's Vaccine R&D Using the ChAd3 Platform

In August 2019, Sabin announced exclusive agreements with GSK for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and Marburg virus. The three candidate vaccines were initially developed collaboratively by the U.S. National Institutes of Health and Okairos, which was acquired by GSK in 2013. The candidate vaccines, based on GSK's proprietary ChAd3 platform, were further developed by GSK, including the Phase II development for the Ebola Zaire vaccine. Under the agreements between GSK and Sabin, Sabin exclusively licensed the technology for all three candidate vaccines and acquired certain patent rights specific to these vaccines.

About the Makerere University Walter Reed Project

MUWRP is a non–profit biomedical research organization with a mission to mitigate disease threats through quality research, health care and disease surveillance. The project's scope includes among others; clinical research in infectious and non–infectious diseases such as HIV, Ebola, Marburg, COVID–19, Influenza and Influenza–like illnesses, and neglected tropical diseases such as Schistosomiasis, among others. A major part of the clinical research are clinical trials, where the MUWRP has conducted more than 12 phase I and II vaccine clinical trials including the first Ebola vaccine trial in Africa.

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662–1841
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0ecbc982–493a–4ecf–9393–e203708aa3ea


GLOBENEWSWIRE (Distribution ID 8952340)

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical–stage oncology company, today announced the closing of its merger with Biosight, Ltd. ("Biosight"), pursuant to which Ayala acquired Biosight. The combined company will operate under the name Ayala Pharmaceuticals, Inc., and its shares will continue to trade on the OTCQX under Ayala's current ticker symbol ("ADXS").

"We are pleased to close the merger with Biosight which expands our product pipeline," said Ken Berlin, President & CEO. "We have added aspacytarabine (BST–236), a novel antimetabolite, which is in clinical development for AML and could potentially serve as a superior backbone therapy for unfit AML as part of combination treatment regimens. Our primary focus continues to be completing the ongoing Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors and we look forward to continuing our mission of bringing innovative therapies to people with rare tumors and aggressive cancers."

Management and Organization

As previously announced, the combined company will be led by Ayala's existing senior management team, with Ken Berlin serving as President and CEO; Andres Gutierrez, MD, PhD, Executive VP and Chief Medical Officer; and Dana Gelbaum, MSc, MBA, General Manager and Chief Business Officer. Roy Golan, CPA, LLM, previously Executive VP & CFO of Biosight, has been appointed Chief Financial Officer of the combined company. The board of directors of the combined company is comprised of David Sidransky, MD (Chairman); Robert Spiegel, MD, FACP; Murray Goldberg; Vered Bisker–Leib, PhD, MBA; Roni Appel, MBA; Pini Orbach, PhD; Yuval Cabilly, PhD; and Ken Berlin, with an additional board member expected to be added at a later date.

About Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc. is a clinical–stage oncology company primarily focused on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The Company's lead candidates under development are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST–236), a novel proprietary anti–metabolite for first line treatment in unfit acute myeloid leukemia (AML). AL102 has received Fast Track Designation from the U.S. FDA and is currently in the Phase 3 segment of a pivotal study for patients with desmoid tumors (RINGSIDE). For more information, visit www.ayalapharma.com.

Contacts:

Ayala Pharmaceuticals:
+1–857–444–0553
info@ayalapharma.com

Media:

Tim McCarthy
LifeSci Advisors, LLC
tim@lifesciadvisors.com
917–679–9282

Cautionary Statement Regarding Forward–Looking Statements

Certain statements contained in this filing may be considered forward–looking statements that involve a number of risks and uncertainties, including statements regarding the future conduct of our studies and the potential efficacy and success of product candidates. Forward–looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions among others. Statements that are not historical facts are forward–looking statements. Forward–looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward–looking statement as a result of various factors, including, without limitation: our ability to integrate Biosight's business successfully with ours and to achieve anticipated synergies; the possibility that other anticipated benefits of the transaction will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of the combined company's operations, and the anticipated tax treatment of the combination; potential litigation relating to the transaction that could be instituted against us, Biosight or our respective directors; possible disruptions from the transaction that could harm our and/or Biosight's respective businesses; the ability of us and Biosight to retain, attract and hire key personnel; potential adverse reactions or changes to relationships with customers, employees, suppliers or other parties resulting from the announcement or completion of the transaction; the success and timing of clinical trials, including subject accrual, the ability to avoid and quickly resolve any clinical holds and the ability to obtain and maintain regulatory approval and/or reimbursement of product candidates for marketing; the ability to obtain the appropriate labeling of products under any regulatory approval; plans to develop and commercialize our products; our ability to continue as a going concern; our levels of available cash and our need to raise additional capital, including to support current and future planned clinical activities; the successful development and implementation of our sales and marketing campaigns; the size and growth of the potential markets for our product candidates and our ability to serve those markets; our ability to successfully compete in the potential markets for our product candidates, if commercialized; regulatory developments in the United States and other countries; the rate and degree of market acceptance of any of our product candidates; new products, product candidates or new uses for existing products or technologies introduced or announced by our competitors and the timing of these introductions or announcements; market conditions in the pharmaceutical and biotechnology sectors; our available cash, including to support current and planned clinical activities; uncertainties as to our ability to obtain a listing of our common stock on Nasdaq; our ability to obtain and maintain intellectual property protection for our product candidates; the success and timing of our preclinical studies including IND–enabling studies; the timing of our IND submissions; our ability to get FDA approval for study amendments; the timing of data read–outs; the ability of our product candidates to successfully perform in clinical trials; our ability to initiate, enroll, and execute pilots and clinical trials; our ability to maintain our existing collaborations; our ability to manufacture and the performance of third–party manufacturers; the performance of our clinical research organizations, clinical trial sponsors and clinical trial investigators; our ability to successfully implement our strategy; legislative, regulatory and economic developments; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management's response to any of the aforementioned factors; and such other factors as are set forth in our periodic public filings with the SEC, including but not limited to those described under the heading "Risk Factors" in the Form 10–K for the fiscal year ended December 31, 2022 of Old Ayala, Inc. (f/k/a Ayala Pharmaceuticals, Inc.) and the Form 10–K for the fiscal year ended October 31, 2022 of Ayala Pharmaceuticals, Inc. (f/k/a Advaxis, Inc.) ("Ayala" or "we," "us" or "our"), and such entities' periodic public filings with the SEC, including but not limited to those described under the heading "Risk Factors" in Ayala's Form 10–K for the fiscal year ended October 31, 2022. Except as required by applicable law, we undertake no obligation to revise or update any forward–looking statement, or to make any other forward–looking statements, whether as a result of new information, future events or otherwise.


GLOBENEWSWIRE (Distribution ID 8951886)

21Shares in another regional first with Shariah compliant digital asset ETPs

A year since listing the region's first digital asset exchange traded product (ETP) on the Nasdaq Dubai, 21Shares secures Shariah approval for its market leading ETPs.

ZURICH/RIYADH, October 19 2023: 21Shares, the world's largest issuer of digital asset ETPs, continues its international expansion with Shariah approval of its 21Shares Bitcoin ETP (ABTC) and21Shares BOLD ETP (BOLD) from leading Saudi scholars.

Having launched the world's first crypto backed ETP in 2018, the company continues to lead the market with the expansion of its products and a catalogue of listings on major global exchanges.

Amidst sustained interest from Saudi investors, the recent Shariah compliance of the BOLD ETP is significant in that the product is at the forefront to become Saudi Arabia's first hybrid product. Rebalanced monthly, BOLD has a 25:75 Bitcoin to gold ratio, offering investors exposure to the traditional value of gold with the promising return rates of Bitcoin.

In the context of inflationary pressures, and heightened geopolitical risk, the products represent important risk and return diversifiers within both private and institutional portfolios.

As regional financial centres compete to provide the latest financial services products, 21Shares' announcement is an important step in the company's Saudi market entry. Under Vision 2030 Saudi Arabia is working to transform its financial services industry highlighted by increased digitalisation across the economy and the widespread adoption of Blockchain.

Ahead of the upcoming Future Investment Initiative, co–founder and CEO Hany Rashwan commented “Saudi Arabia presents exciting new market expansion opportunities for us. This milestone reflects our unwavering commitment to operating within the highest regulatory standards and providing a secure and transparent platform for our clients. Our tailored crypto investment solutions will resonate with Saudi investors. We look forward to partnering with local financial institutions, fostering trust, and contributing to the Kingdom's thriving fintech ecosystem.”


About 21.co
21.co is the world's leader in providing access to crypto through TradFi and DeFi. 21.co offers cryptocurrency exchange traded products (ETPs) via its 21Shares affiliate, as well as blockchain infrastructure technology. 21.co's products are built on its proprietary operating system, Onyx, which is also distributed to third parties. The company was founded in 2018 by Hany Rashwan and Ophelia Snyder. For more information, please visit www.21.co.

Press Contact
Nicole Cueto, press@21.co

Disclaimer
The information provided does not constitute a prospectus or other offering material and does not contain or constitute an offer to sell or a solicitation of any offer to buy securities or financial instruments in any jurisdiction, including the U.S. Some of the information published herein may contain forward–looking statements and readers are cautioned that any such forward looking statements are not guarantees of future performance, involve risks and uncertainties, and actual results may differ. Additionally, there is no guarantee as to the accuracy, completeness, timeliness or availability of the information provided and 21.co and its affiliated entities are not responsible for any errors or omissions. The information contained herein may not be considered as economic, legal, tax or other advice and viewers are cautioned not to base investment or any other decisions on the content hereof.


GLOBENEWSWIRE (Distribution ID 1000864821)

Big Changes Coming to the World Bank—But it’s Not Enough

Credit: European Press Agency for Glasgow Actions Team

By Andrew Nazdin
LONDON, Oct 19 2023 – It’s official: The World Bank officially has a mission to combat climate change. At least on paper.

This week, the World Bank governing body approved a new vision statement that clarifies that the Bank can tackle climate change as part of its mission to alleviate global poverty on “a livable planet.” Also this week, the new World Bank President Ajay Banga suggested that he’ll be consider redirecting subsidies away from fossil fuels and towards climate action.

This is not nearly enough. The World Bank is still funneling billions of dollars to the fossil fuel industry each year, through direct and indirect finance mechanisms. Urgewald estimates that they funded $3.7 billion towards oil and gas last year.

This is despite the fact that they’ve made a commitment to align with the Paris Climate Agreement and do what it takes to keep global warming under 1.5 degrees Celsius. In order to do so, experts with the International Energy Agency warned that there is ‘no room’ for new fossil fuel development if we’re going to reach this goal.

The IEA also said that fossil fuel subsidies are an inefficient way to help consumers. Yet despite this, Banga admitted he didn’t plan to “get rid of all” fossil fuel subsidies. Just that the topic “needs discussion.”

Still – it’s hard to imagine this new vision statement coming out one year ago, under the helm of former climate change-denying president David Malpass. After his climate change denial caused public outrage–and protests around the world–he stepped down, and US President Joe Biden appointed a new president.

Credit: European Press Agency for Glasgow Actions Team

Banga started with a clear societal mandate to accelerate climate action at the World Bank. He was given a 100-day plan to end fossil fuel finance, fund a just and green transition, and promote transparency.

Last week, Banga’s opportunity arrived during the World Bank Group and International Monetary Fund Annual Meetings in Marrakech. The first meetings run by Banga after months of him talking up his climate change credentials.

Organizations from around the world teamed up with local Moroccan activists to put on the pressure. It started before the meetings began, with billboards blanketing the city. They had two key demands: End Fossil Finance and Drop the Debt.

Why end fossil finance?

Because the World Bank, despite its commitments to the Paris Climate Agreement, has continued funneling billions of dollars to fossil fuel projects through direct and indirect mechanisms.

And why drop the debt?

Because global debt is at a decades-long high, with people in 54 countries currently living in debt crisis, and unless these colonial debt deals can be fixed, many developing countries can’t afford to invest in the climate solutions they so desperately need.

The action continued all week long. On the first day of the meetings, we stood outside the meeting venue to greet every World Bank delegate on their way inside. Many groups joined the meetings and delivered a petition to Banga himself, with 40,000 people calling on him to end fossil finance.

Last Thursday, hundreds marched through the streets of Marrakech. And on the final day of the conference, activists returned to the conference venue for one last rousing rally and day of action.

Meanwhile, the Bank must consider the intertwined relationship between debt relief for developing nations and environmental sustainability. Offering debt relief can free up resources, enabling these nations to explore and invest in green technologies.

This would not only aid in their fight against climate change but also propel them toward a sustainable economic trajectory. Banga has outlined a few steps to greatly increase funding that can flow through the World Bank.

But we must make sure such increased funding doesn’t continue to force developing countries into deals they can never get out of. It’s true that the world needs vastly more funding into clean energy industries if we are to transition to a sustainable economy. We need funding that helps those in need, not harms.

The World Bank acknowledging that it must do its job on a “livable planet” is the absolute bare minimum. It’s like an employee setting his printer on fire but telling his manager, “At least I didn’t burn the whole office down.”

Decades after the world’s top scientists have agreed that climate change is an existential threat, the Bank has a place for climate change in its vision statement. But what is a vision without a plan? And what is a plan on a dead planet?

The protestors have done their part, articulating a vision for a greener, fairer world economy. The ball now lies firmly in the court of institutions like the World Bank. As the drums of activism fade and the placards are put away, the world awaits their next move.

What will it be?

Andrew Nazdin is Director of Glasgow Actions Team

The Glasgow Actions Team formed around the UN Climate Conference in 2021 in Glasgow, which led to a landmark deal putting the world on the trajectory to ending financing for fossil fuels. The organization is committed to pushing the world’s climate champions to go farther, calling out the blockers, and exposing the deniers. Throughout the 2023 Annual Meetings of the World Bank Group, they ran several actions calling on the World Bank to get in line with the Paris Climate Goals — to stop funding fossil fuels, invest in renewables, and become a more transparent and democratic institution.

To learn more, follow Glasgow Actions Team on Twitter, Instagram, , or check out the website.

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

South Asian Community Health Workers Say Their Work is Work

Community health workers demand to be recognised as formal workers with pay and benefits to match. Credit: Zofeen T. Ebrahim

Community health workers demand to be recognised as formal workers with pay and benefits to match. Credit: Zofeen T. Ebrahim

By Zofeen Ebrahim
KARACHI, Oct 19 2023 – “Professionally, I am still where I was 23 years ago when I started working as a lady health worker (LHW),” said a disgruntled Yasmin Siddiq, 47, from Karachi. “I will probably retire in the same capacity, as a Grade 5 government servant, without any hope for upward mobility.”

The idea behind the Lady Health Worker Programme (LHWP), the brainchild of Pakistan’s late prime minister Benazir Bhutto, began in 1994 with the purpose of “training women as community health workers (CHWs) to improve the dismal maternal and child health scores of the country and build a bridge between the village woman and the formal health sector,” said Dr Talat Rizvi, a public health physician with a vast experience in Maternal and Child Health with a particular focus on community-based projects and who designed the programme.

Siddiqi’s day starts at 9 am, and she must go door-to-door, covering between 5 to 10 homes within the 1 km radius of her home. “Initially, my tasks included making married women (of reproductive age) aware of the benefits of family planning and informing and providing them assistance about contraceptives, ensuring they go for antenatal check-ups when pregnant and their tetanus shots. I had to keep an eye on under-five children of that family and get them vaccinated,” she said. Over the years, her workload has expanded.

“We were asked to help fight TB, handle refusals by parents on administration of polio drops, ensure every child under five gets immunised against childhood diseases, which have now increased to 12 vaccines, and recently during the COVID-19 pandemic, we helped with vaccinations,” said Bushra Bano Arain, chairperson of All Pakistan Lady Health Workers Union. “And as if health is not enough, we are asked to carry out our duties on election day,” disclosed Arain, an LHW supervisor.

“Over the years, the focus got diluted from primary healthcare when more and more responsibilities were added to the LHWP’s boat, and the boat sank,” said Rizvi.

“The original programme of ensuring the health of mother and child took a backseat,” agreed Dr Shershah Syed, a gynaecologist and obstetrician. “LHW was perhaps started with good intention but had become a politicised entity with many women recruited by MPAs and MNAs as ghost workers, in the Sindh province especially,” he added.

The situation is no better for the over a million Accredited Social Health Activists (ASHAs)  in India or the 52,000 Female Community Health Volunteers (FCHVs) of Nepal, who have, over the years, been lumped with more and more tasks, according to Public Services International, a global trade union federation, which helped the women CHWs in Pakistan, Nepal and India come up with a Charter of Demands to “address injustices and advocate for better working conditions”.

According to Jeni Jain Thapa, PSI’s project organiser in Nepa, the FCHVs “have no fixed working hours and must be on standby 24/7”.

The same is the case with the LHWs, said Musarrat Basharat, an LHW and the general secretary of the Punjab LHW’s Union. “Whatever time of the day or night it is, we must accompany a woman in labour to the health centre and be with her till she delivers. Same with a sick child. If the baby has diarrhoea and is dehydrated, we must rehydrate and be with the family for six hours until the child is out of danger. We are not shirking from our duty, but at least pay us for overtime or make some provision for it,” she said.

However, of the CHWs in the three countries, over 100,000 LHWs have won significant gains in getting themselves recognised as workers, securing a wage and registering their unions, Kannan Raman, secretary PSI, South Asia: “In Nepal and India, they are considered volunteers and not offered decent wages or better working conditions.”

“It took us 20 years to get ourselves noticed when the Supreme Court of Pakistan asked the government to bring us into the fold of formal work and make us permanent employees in 2014,” said Haleema Leghari, central president of All Sindh Lady Health Workers and Employees Union, working as a supervisor in the LHW programme.

But even after nine years, they continue working without a job structure or rules that go with that. “We rejected the service structure made for us as it was found to be discriminatory,” said Leghari, adding: “Recognition from the government is mere lip service.”

Even for those who started in 1994, like Arain and Leghari, who have become supervisors, their grades have been marginally improved from Grade 5 (which is for LHWs) to Grade 7 (which is for the supervisor). “While in other sections of the health departments, those who have worked as many years as us and are as educated as us have reached Grade 14; why have we not been upgraded?” Arain asked.

Although their salary was increased by 35 percent in June, Leghari said: “We do not want these ad-hoc increments; we want promotions like other government servants are promoted based on work performance, education and years of service, as these impromptu increments can also be taken back anytime.”

In addition, she said that those who have retired after attaining 60 years of age, are sick, or have died should be compensated. They or their families should be paid the pension in arrears,” she added. Today, the LHWs want the 20 years of contract work to be accounted for, which they say “everyone seems to have forgotten”.

According to Leghari, in other government departments, when an employee retires or meets with an accident, is sick or dies, a family member gets the job in that department. “We are missing out on these benefits because the rules have not been approved in the absence of a service structure,” she said.

“Their main demand is fool-proof security,” said Mir Zulfiqar Ali, executive director of Workers Education and Research Organisation. “You know so many LHWs have been killed by extremists,” he said. His organisation is working with the LHWs and training them about labour rights, health protection especially during crises and pandemics, and workplace safety and how to lobby effectively with the government to get their demands accepted, coordinating the PSI CHW project in Pakistan.

Siddiqi’s monthly payment is now Rs 44,000 from Rs 37,000 since June, but given the skyrocketing food, electricity and fuel prices, she said this was certainly not enough for a single mother with two school and college-going kids.

“The provincial health departments have time to meet all the international NGOs and donor agencies, but for holding a meeting to address our grievances, they can never find time,” said Arain.

“The invaluable work community health workers do work that has delivered immeasurable value to communities and public health, is not valued, simply because it is carried out by women, and women’s care work is routinely de-valued, even when it saves lives”, explained Kate Lappin, the Asia Pacific regional secretary for PSI.

With new climate catastrophes imminent, Lappin said Pakistan will need the services of LHWs even more, as was proved during the pandemic and the 2022 floods that disrupted the already fragile health system. “They [CHWs] are the first line of defence in a crisis.” She was in Pakistan recently and met with LHWs from some remote parts of Pakistan. “It was clear that they are often the only source of support to women in the most underserviced areas.”

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);